A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients

Junzo Nojima, Yukari Motoki, Natsumi Aoki, Hidehiro Tsuneoka, Kiyoshi Ichihara

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Background Anti-phospholipid antibodies (aPLs) are frequently associated with arterial and/or venous thromboembolic complications and recurrent fetal loss in patients with systemic lupus erythematosus (SLE). We recently reported that the clinical picture of SLE apparently depends on subclasses of aPLs in the patient's sera, but the contribution of each subclass remains uncertain. Methods We newly developed an ELISA system for simultaneous detection of six specific categories of aPLs: anti-cardiolipin (aCL), anti-β2- glycoprotein I (aβ2GPI), anti-cardiolipin/β2- glycoprotein I (aCL/β2GPI), anti-phosphatidylserine (aPS), anti-prothrombin (aPT), and anti-phosphatidylserine/prothrombin (aPS/PT). They were measured in 331 patients with SLE including 63 patients with arterial thromboembolic complications, 64 with venous thromboembolic complications, and 43 with recurrent fetal loss. Lupus anticoagulant (LA) activity in their plasma was measured according to the guidelines recommended by the Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies. Results Multivariate logistic analysis revealed that the concentration of aPS/PT was most closely associated with arterial thrombosis. In contrast, the concentration of aβ2GPI was most closely related to venous thrombosis. Furthermore, both aCL/β2GPI and aPS/PT were independently associated with episodes of recurrent fetal loss. Regarding the relation between APLs and LA activity, aPS/PT, followed by aβ2GPI and aPT, showed the closest association with the presence of LA activity. Conclusions Anti-phospholipid syndrome in patients with SLE can be classified by antigenic specificities of their aPLs as to their susceptibility to arterial and/or venous thromboembolic complications or obstetric complications.

    Original languageEnglish
    Pages (from-to)1135-1140
    Number of pages6
    JournalThrombosis Research
    Volume133
    Issue number6
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Phosphatidylserines
    Lupus Coagulation Inhibitor
    Systemic Lupus Erythematosus
    Anti-Idiotypic Antibodies
    Phospholipids
    Enzyme-Linked Immunosorbent Assay
    Cardiolipins
    Glycoproteins
    Prothrombin
    Antiphospholipid Syndrome
    Venous Thrombosis
    Obstetrics
    Epitopes
    Thrombosis
    Multivariate Analysis
    Guidelines
    Antibodies
    Serum

    Keywords

    • anti-phosphatidylserine/prothrombin antibodies
    • Systemic lupus erythematosus
    • Thrombotic complications

    ASJC Scopus subject areas

    • Hematology
    • Medicine(all)

    Cite this

    A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients. / Nojima, Junzo; Motoki, Yukari; Aoki, Natsumi; Tsuneoka, Hidehiro; Ichihara, Kiyoshi.

    In: Thrombosis Research, Vol. 133, No. 6, 2014, p. 1135-1140.

    Research output: Contribution to journalArticle

    Nojima, Junzo ; Motoki, Yukari ; Aoki, Natsumi ; Tsuneoka, Hidehiro ; Ichihara, Kiyoshi. / A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients. In: Thrombosis Research. 2014 ; Vol. 133, No. 6. pp. 1135-1140.
    @article{e8516c0b822543c5b677e42ab42bf99e,
    title = "A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients",
    abstract = "Background Anti-phospholipid antibodies (aPLs) are frequently associated with arterial and/or venous thromboembolic complications and recurrent fetal loss in patients with systemic lupus erythematosus (SLE). We recently reported that the clinical picture of SLE apparently depends on subclasses of aPLs in the patient's sera, but the contribution of each subclass remains uncertain. Methods We newly developed an ELISA system for simultaneous detection of six specific categories of aPLs: anti-cardiolipin (aCL), anti-β2- glycoprotein I (aβ2GPI), anti-cardiolipin/β2- glycoprotein I (aCL/β2GPI), anti-phosphatidylserine (aPS), anti-prothrombin (aPT), and anti-phosphatidylserine/prothrombin (aPS/PT). They were measured in 331 patients with SLE including 63 patients with arterial thromboembolic complications, 64 with venous thromboembolic complications, and 43 with recurrent fetal loss. Lupus anticoagulant (LA) activity in their plasma was measured according to the guidelines recommended by the Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies. Results Multivariate logistic analysis revealed that the concentration of aPS/PT was most closely associated with arterial thrombosis. In contrast, the concentration of aβ2GPI was most closely related to venous thrombosis. Furthermore, both aCL/β2GPI and aPS/PT were independently associated with episodes of recurrent fetal loss. Regarding the relation between APLs and LA activity, aPS/PT, followed by aβ2GPI and aPT, showed the closest association with the presence of LA activity. Conclusions Anti-phospholipid syndrome in patients with SLE can be classified by antigenic specificities of their aPLs as to their susceptibility to arterial and/or venous thromboembolic complications or obstetric complications.",
    keywords = "anti-phosphatidylserine/prothrombin antibodies, Systemic lupus erythematosus, Thrombotic complications",
    author = "Junzo Nojima and Yukari Motoki and Natsumi Aoki and Hidehiro Tsuneoka and Kiyoshi Ichihara",
    year = "2014",
    doi = "10.1016/j.thromres.2014.03.032",
    language = "English",
    volume = "133",
    pages = "1135--1140",
    journal = "Thrombosis Research",
    issn = "0049-3848",
    publisher = "Elsevier Limited",
    number = "6",

    }

    TY - JOUR

    T1 - A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients

    AU - Nojima, Junzo

    AU - Motoki, Yukari

    AU - Aoki, Natsumi

    AU - Tsuneoka, Hidehiro

    AU - Ichihara, Kiyoshi

    PY - 2014

    Y1 - 2014

    N2 - Background Anti-phospholipid antibodies (aPLs) are frequently associated with arterial and/or venous thromboembolic complications and recurrent fetal loss in patients with systemic lupus erythematosus (SLE). We recently reported that the clinical picture of SLE apparently depends on subclasses of aPLs in the patient's sera, but the contribution of each subclass remains uncertain. Methods We newly developed an ELISA system for simultaneous detection of six specific categories of aPLs: anti-cardiolipin (aCL), anti-β2- glycoprotein I (aβ2GPI), anti-cardiolipin/β2- glycoprotein I (aCL/β2GPI), anti-phosphatidylserine (aPS), anti-prothrombin (aPT), and anti-phosphatidylserine/prothrombin (aPS/PT). They were measured in 331 patients with SLE including 63 patients with arterial thromboembolic complications, 64 with venous thromboembolic complications, and 43 with recurrent fetal loss. Lupus anticoagulant (LA) activity in their plasma was measured according to the guidelines recommended by the Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies. Results Multivariate logistic analysis revealed that the concentration of aPS/PT was most closely associated with arterial thrombosis. In contrast, the concentration of aβ2GPI was most closely related to venous thrombosis. Furthermore, both aCL/β2GPI and aPS/PT were independently associated with episodes of recurrent fetal loss. Regarding the relation between APLs and LA activity, aPS/PT, followed by aβ2GPI and aPT, showed the closest association with the presence of LA activity. Conclusions Anti-phospholipid syndrome in patients with SLE can be classified by antigenic specificities of their aPLs as to their susceptibility to arterial and/or venous thromboembolic complications or obstetric complications.

    AB - Background Anti-phospholipid antibodies (aPLs) are frequently associated with arterial and/or venous thromboembolic complications and recurrent fetal loss in patients with systemic lupus erythematosus (SLE). We recently reported that the clinical picture of SLE apparently depends on subclasses of aPLs in the patient's sera, but the contribution of each subclass remains uncertain. Methods We newly developed an ELISA system for simultaneous detection of six specific categories of aPLs: anti-cardiolipin (aCL), anti-β2- glycoprotein I (aβ2GPI), anti-cardiolipin/β2- glycoprotein I (aCL/β2GPI), anti-phosphatidylserine (aPS), anti-prothrombin (aPT), and anti-phosphatidylserine/prothrombin (aPS/PT). They were measured in 331 patients with SLE including 63 patients with arterial thromboembolic complications, 64 with venous thromboembolic complications, and 43 with recurrent fetal loss. Lupus anticoagulant (LA) activity in their plasma was measured according to the guidelines recommended by the Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies. Results Multivariate logistic analysis revealed that the concentration of aPS/PT was most closely associated with arterial thrombosis. In contrast, the concentration of aβ2GPI was most closely related to venous thrombosis. Furthermore, both aCL/β2GPI and aPS/PT were independently associated with episodes of recurrent fetal loss. Regarding the relation between APLs and LA activity, aPS/PT, followed by aβ2GPI and aPT, showed the closest association with the presence of LA activity. Conclusions Anti-phospholipid syndrome in patients with SLE can be classified by antigenic specificities of their aPLs as to their susceptibility to arterial and/or venous thromboembolic complications or obstetric complications.

    KW - anti-phosphatidylserine/prothrombin antibodies

    KW - Systemic lupus erythematosus

    KW - Thrombotic complications

    UR - http://www.scopus.com/inward/record.url?scp=84900520533&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84900520533&partnerID=8YFLogxK

    U2 - 10.1016/j.thromres.2014.03.032

    DO - 10.1016/j.thromres.2014.03.032

    M3 - Article

    C2 - 24721837

    AN - SCOPUS:84900520533

    VL - 133

    SP - 1135

    EP - 1140

    JO - Thrombosis Research

    JF - Thrombosis Research

    SN - 0049-3848

    IS - 6

    ER -